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Varicella-zoster virus (VZV) causes chickenpox
and shingles. While varicella is likely spread as
cell-free virus to susceptible hosts, the virus is
transmitted by cell-to-cell spread in the body
and in vitro. Since VZV glycoprotein E (gE) is
essential for virus infection, we postulated that
gE binds to a cellular receptor.We found that in-
sulin-degrading enzyme (IDE) interacts with gE
through its extracellular domain. Downregula-
tion of IDE by siRNA, or blocking of IDE with an-
tibody, with soluble IDE protein extracted from
liver, or with bacitracin inhibited VZV infection.
Cell-to-cell spread of virus was also impaired
by blocking IDE. Transfection of cell lines im-
paired for VZV infection with a plasmid express-
ing human IDE resulted in increased entry and
enhanced infection with cell-free and cell-asso-
ciated virus. These studies indicate that IDE is
a cellular receptor for both cell-free and cell-
associated VZV.
INTRODUCTION
Varicella-zoster virus (VZV) is the etiologic agent of vari-
cella (chickenpox) and zoster (shingles). VZV is a member
of the a-herpesvirus family and is closely related to the
other two human virus members of the family, herpes sim-
plex virus (HSV) 1 and 2. Acute infection with VZV is fol-
lowed by cell-associated viremia and the rash of varicella
(Arvin, 2001). The virus establishes latency in the nervous
system and can reactivate to cause zoster. While varicella
is likely transmitted by cell-free airborne virions, in cell
culture VZV is highly cell associated, and the virus is prop-
agated by cell-to-cell spread with no infectious virus pres-
ent in themedium. The virus is thought to spreadwithin the
body by cell-to-cell transfer of virus.
Themechanismof VZV entry into target cells and spread
from cell-to-cell is not well understood. Previous studies
showed that VZV, like other members of the herpesvirusfamily, engages cell surface heparan sulfate for initial
attachment (Zhu et al., 1995). Mannose 6-phosphate
inhibits infection with cell-free VZV, which implicates the
cation-independent mannose 6-phosphate receptor
(MPRci) in facilitating entry of cell-free virus by interacting
with viral glycoproteins that contain phosphorylated
N-linked complex oligosaccharides (Gabel et al., 1989;
Zhu et al., 1995). Chen et al. (2004) used stable cell lines
deficient in MPRci to show that the protein is required for
infection by cell-free VZV (Chen et al., 2004). However, sol-
uble MPRci did not bind to viral glycoproteins in ligand-
blotting assays (Zhu et al., 1995). Cell lines deficient in
MPRci are not impaired for infection by cell-associated
virus; thus, MPRci is not a cellular receptor for cell-to-cell
spread of the virus.
Studies of HSV-1 and HSV-2 have identified viral and/or
cellular proteins required for entry and cell-to-cell spread.
Herpes virus entry mediator A, nectin-1 and nectin-2, and
3-O-sulfated heparan sulfate have each been established
as HSV receptors for entry of cell-free virus (Cocchi et al.,
1998; Geraghty et al., 1998; Montgomery et al., 1996;
Shukla et al., 1999). HSV glycoprotein D (gD) has been
identified as the viral ligand for each of these receptors.
HSV gE/gI, though not essential for entry and replication,
sorts nascent virions to cell junctions and is required for
efficient cell-to-cell spread of HSV (Collins and Johnson,
2003; Dingwell and Johnson, 1998). Although a cellular re-
ceptor for gE/gI has been postulated, it has not yet been
identified.
VZV encodes at least seven glycoproteins, gB, gC, gE,
gH, gI, gK, gL, all of which have well-conserved homologs
in HSV (Cohen and Straus, 2001). In contrast to HSV, VZV
does not have a homolog for gD. While HSV gD is one of
five glycoproteins in the unique short region of its genome,
the corresponding portion of VZV encodes only two VZV
glycoproteins, gE and its chaperon gI. Since HSV gD is
the receptor binding protein for HSV, and VZV gI is not re-
quired for infection by VZV (Cohen and Nguyen, 1997),
VZV gE might be important for binding to a cellular recep-
tor. HSV gE or HSV gD alone do not mediate membrane
fusion. The minimum requirement for HSV fusion to cells
is the coexpression of four glycoproteins (gD, gB, gH,
and gL) and a cell-surface entry receptor specific for gDCell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc. 305
(Pertel et al., 2001). Syncytia formation in VZV, a hallmark
of cell-to-cell spread, is due to fusion of cell membranes
mediated by gH and gL, or gB and gE (Cole and Grose,
2003).While expression of gHor gBalone induce amodest
amount of fusion, expression of gE alone is not sufficient
for fusion unless it is coexpressed with gB (Maresova
et al., 2001). Attempts to generate a VZV gE deletion mu-
tant were unsuccessful (Mo et al., 2002), and a gE minus
virus could only be constructed using cells expressing
gE (Q.L. and J.C., unpublished data). Taken together,
these findings indicate that VZV gE is an essential glyco-
protein for VZV. Antibodies to gE neutralize virus in vitro,
and immunization with a vector expressing gE protects
animals from challenge with virus (Lowry et al., 1992; Wu
and Forghani, 1997). Therefore, VZV gE may be involved
in viral entry and cell-to-cell spread and is a likely candi-
date for binding to a cellular receptor.
In this study we identified insulin-degrading enzyme
(IDE) as a cellular receptor for gE. IDE forms a complex
with both the purified extracellular domain and the native
form of gE in VZV-infected cells. Inhibition of IDE results
in reduced VZV infectivity and cell-to-cell spread. Expres-
sion of human IDE in nonhuman cell lines that are impaired
for VZV infection enhanced virus infection, entry, and bind-
ing. These experiments identify IDE as a VZV receptor and
confirm the essential role that gE plays in VZV infection.
RESULTS
The Extracellular Domain of gE Interacts with IDE
VZV gE is essential for virus replication andmay be impor-
tant for virus entry. To identify cellular ligands that interact
with gE, a soluble form of the extracellular domain of gE
fused to human Ig Fc was immobilized on protein A-Se-
pharose beads and used in a pull-down assay with cell ly-
sates from human melanoma cells that are permissive for
VZV infection. After extensive washing, the bound pro-
teins were resolved on SDS-PAGE gels and stained with
Coomassie blue. A unique band of about 120 kDa
(Figure 1A) was pulled down by the gE-Fc fusion protein
but was absent from protein lysates incubated with Se-
pharose alone or control Fc fusion proteins. The band
was excised, and sequencing identified the protein as IDE.
To confirm the interaction of gEwith IDE and rule out the
possibility of binding to the Fc tag, pull-down assays were
performed using truncated gE without an Fc tag (gEt) im-
mobilized onto protein A-Sepharose beads with monoclo-
nal antibody to gE and incubated with lysates from HeLa
cells or human T cells. After extensive washing, the beads
were boiled in sample buffer, subjected to SDS-PAGE
separation, transferred to membranes, and immunoblot-
ted with polyclonal anti-IDE antibody. gEt formed a com-
plex with IDE that was detected with antibody to gE in
both HeLa and T cells (Figure 1B, lanes 5–6) but not in
HeLa cells when a control antibody was used in place of
antibody to gE (Figure 1B, lane 4). IDE also bound to gE
in VZV-infected melanoma cells. Immunoprecipitation of306 Cell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc.gE with anti-gE antibody followed by immunoblotting
with anti-IDE antibody indicated that gE interacted with
IDE in VZV-infected but not uninfected cells (Figure 1B,
lanes 1–3).
gB and gH play important roles in viral entry and/or
infectivity of herpesviruses. We tested whether IDE inter-
acts with VZV gB, VZV gH, VZV gI, or HSV gE. Lysates
from VZV-infected cells were immunoprecipitated with
antibodies to VZV gE, gB, or gH and immunoblotted
with anti-IDE antibody. While gE coimmunoprecipitated
with IDE, gB and gH did not interact with IDE (Figure 1C,
lanes 7–9). Transfection of CV-1 cells with plasmids
expressing VZV gE, VZV gI, or HSV gE followed by immu-
noprecipitation with the corresponding antibody and
immunoblotting with anti-IDE antibody showed that the
extracellular domain of VZV gI, which functions as a gE
chaperone but lacks sequence homology with gE, also
interacted with IDE, although at a much weaker level than
gE (Figure 1C, lanes 1 and 2). This was confirmed using
an ELISA-based ligand binding assay. When similar levels
of His-tagged soluble gE, gI, or gB were incubated with
HA-IDE, the latter bound significantly greater to gE than
toeither gBorgI over a rangeof concentrations (Figure 1D).
HSV gE, which has 32% amino acid identity with VZV gE
within a 170 amino acid region, interacted very weakly
with IDE (Figure 1C, lane 4).
Immunoprecipitation of IDE from infected cells followed
by immunoblotting with antibody to gE showed that the
amount of gE-IDE complexes increased during the course
of VZV infection (Figure S3), which was in parallel with the
increasing amounts of gE produced in these infected cells
over time, even though the total amount of IDE remained
unchanged (data not shown).
A Portion of IDE that Interacts with gE Is Located
on the Plasma Membrane
Computer analysis indicates that the predicted sequence
of IDE contains a putative amino-terminal signal peptide
with a potential cleavage site between residues 22 and
23, and the majority of the sequence might be extracellu-
lar; however, a typical transmembrane domain is not ap-
parent (TMHMM program, Technical University of Den-
mark). Cell fractionation studies showed that IDE is
localized primarily in the cytosol (Akiyama et al., 1988),
with a small amount present on the cell-surface plasma
membrane (Seta and Roth, 1997; Yaso et al., 1987). Vek-
rellis et al. (2000) identified a115 kDa cell-surface mem-
brane-associated IDE isoform on neuronal cells (Vekrellis
et al., 2000). To verify that IDE is present on the surface
of cells, we biotinylated cell surface proteins followed by
immunoprecipitation with streptavadin-coated agarose
beads and immunoblotting with anti-IDE antibody. A pro-
tein of 120 kDa was present on the surface of HeLa and
melanoma cells (Figure 2A, lanes 1 and 2).
To determine whether gE interacts with IDE on the
plasma membrane, cell-surface proteins were biotiny-
lated and incubated with gEt. The IDE-gE complex was
immunoprecipitated with gE antibody followed by
Figure 1. IDE Interacts with the Extracellular Domain of VZV gE but Not gB or gH
(A) The extracellular domain of gE fused to the Fc portion of human IgG (gE-Fc) bound to protein-A Sepharose was incubated with a cell lysate from
melanoma cells, and proteins that bound to gE-Fc were resolved on SDS-PAGE and stained with Coomassie blue. A 120 kDa cellular protein is pres-
ent in the cell lysate that interacts with gE-Fc.
(B) gE protein from VZV ROka-infected cells (lane 1) or VZV Molly, a low-passage clinical isolate (lane 2), was immunoprecipitated with monoclonal
anti-gE antibody, and IDE was detected in immune complexes. Purified extracellular domain of gE (gEt) immobilized onto protein-A Sepharose beads
with anti-gE antibody (lanes 5 and 6) pulls down IDE from cell lysates.
(C) Plasmids encoding the extracellular domain of VZV gE (lane 1), gI (lane 2), full-length HSV gE (lane 4), or control vectors (lanes 3 and 5) were trans-
fected into CV-1 cells, and immunoprecipitation with the respective antibodies pull down IDEwith VZV gE and, to a lesser extent, with gI. Lysates from
VZV-infected cells immunoprecipitated with anti-gE, but not with anti-gB or anti-gH, antibody pull down IDE (lanes 7–9).
(D) ELISA plates were coated with HA-IDE and incubated with equal amounts of His-tagged gEt, gBt, or gIt, and binding was assayed using anti-His
antibody. HA-IDE binds to gEt significantly greater than to gIt or gBt. Error bars show standard deviations, and t test was used to determine p values.immunoblotting with streptavidin-conjugated HRP to de-
tect cell surface IDE or anti-IDE antibody to detect total
IDE. A portion of the total IDE in the gE-IDE complex
was derived from IDE on the cell surface (Figure 2B, lanes
2 and 6). Controls lacking antibody to gE showed that the
IDE-gE interaction was required for detection of IDE on the
cell surface in this assay (Figure 2B, lanes 3 and 4).
Anti-IDE Antibodies and Soluble IDE Extracted from
Liver Reduce VZV Infectivity and Cell-to-Cell Spread
Polyclonal and monoclonal IDE antibodies were tested for
their ability to block VZV infection. Commercially available
polyclonal anti-IDE antibody PRB-282C and monoclonal
antibody 9B12 (Covance, Berkeley, CA) were used. In sev-eral experiments, addition of either antibody (50 ug/ml for
9B12 and 1/200 dilution for PRB-282C serum) to MeWo
cells prior to VZV infection resulted in 30%–45% inhibition
of virus infectivity (Figures 3A and 3B), while a control an-
tibody (anti-CD3) or normal rabbit serum showed little or
no effect. Polyclonal antibody (Figure S4) blocked VZV
infection in a dose-dependent manner.
To determine if IDE antibody affects cell-to-cell spread
of VZV, we preincubated cells with the polyclonal antibody
at 1/100 to 1/200 dilutions at 4C for 60 min followed by
infection with cell-free ROka-lacZ in the presence of the
antibody. Three days later the cells were stained with
X-gal. IDE antibody markedly reduced plaque sizes com-
pared to the cells treated with control normal rabbit serumCell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc. 307
Figure 2. The Extracellular Domain of gE Interacts with IDE on the Surface of Cells
(A) Biotinylated cell-surface proteins that were precipitated with streptavidin-coated agarose beads pull down IDE from the surface of HeLa (lane 1) or
melanoma (lane 2) cells as detected by immunoblottingwith antibody to IDE. In the absence of biotinylation, IDE is not detected on the surface of HeLa
(lane 3) or melanoma (lane 4) cells.
(B) Monolayers of CV-1/EBNA-1 cells were biotinylated for 30 min at room temperature in PBS to label cell-surface proteins. After extensive washing,
the cells were lysed and incubated with soluble gEt that had been immobilized on beads using anti-gE antibody. After washing, the beads were boiled
in SDS-protein gel solution, and a 120 kDa protein was detected after blotting with Streptavidin-HRP to detect cell-surface IDE, or with anti-IDE to
detect total IDE. Lane 9 represents lysate not incubated with beads.(Figure 3C). Therefore, IDE antibody inhibits cell-to-cell
spread of VZV.
To determine whether purified soluble IDE can inhibit
entry of VZV, we incubated cell-free ROka-lacZ with solu-
ble IDE extracted from liver or uninfected sonicated cell
protein as a control, at 37C for 30 min before infection
of melanoma cells. Four days postinfection the cells
were stained with X-gal and the number of blue foci, indic-
ative of infectivity by cell-free virus, were scored. Soluble
IDE inhibited infectivity by 70%, while control protein
had no effect (Figure 3D). In three independent experi-
ments, IDE inhibited VZV infectivity by 50%–70%. In con-
trast, when soluble IDE was added at 1.5 hr after infection,
it failed to reduce the number of VZV foci (data not shown),
suggesting that soluble IDE extracted from liver blocks
VZV entry during the initial stages of infection.
To determine if soluble IDE extracted from liver affects
cell-to-cell spread of VZV, we infected cells with cell-free
ROka-lacZ in the presence of soluble IDE or control pro-
tein (37.5 mg/ml each) and added the proteins again on
the second day of infection. Two days later the cells
were stained with X-gal. Soluble IDE markedly reduced
plaque sizes compared to the cells treated with control
protein or no added protein (Figure 3E). Therefore, soluble
IDE inhibits cell-to-cell spread of VZV.
Interestingly, VZV infectivity was enhanced when the vi-
rus was pretreated with recombinant soluble IDE (rIDE)
produced in a baculovirus expression system (Figure 3F).
rIDE is initiated from the second ATG of the IDE coding se-
quence and thus is missing the first 41 amino acids of the
protein. Since rIDE is produced in insect cells, it may be
processed differently than IDE extracted from liver. The
enhancement of VZV infectivity by rIDE supports a role
for IDE in an early stage of VZV infection. Several soluble
receptor molecules have been described that can either
block or promote virus infection, including nectin-1 for
HSV (Kwon et al., 2006; Lopez et al., 2001) and sCD4 for
HIV (Sattentau and Moore, 1991; Smith et al., 1987).308 Cell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc.Since IDE interacts with gE, and IDE degrades several
proteins, including insulin (Farris et al., 2003; Goldfine
et al., 1984) and amylin (Farris et al., 2003; Vekrellis
et al., 2000), we determined whether IDE degrades gE. In-
cubation of purified IDEwith gEt at 37C for 4 hr did not re-
duce the amount of the glycoprotein, while IDE degraded
insulin when incubated at 37C for 30 min (Figure S1A).
Conversely, addition of bacitracin (1 mg/ml), an IDE inhib-
itor that reduces degradation of insulin and amylin by IDE
(Bennett et al., 2003), did not change the turnover rate of
gE in VZV-infected cells during a pulse-chase experiment
(Figure S1B). These results suggest that IDE is not impor-
tant for degradation of gE in cells.
Knockdown of IDE Expression Inhibits VZV Infection
and Cell-to-Cell Spread
To determine the role of IDE in VZV infection, we used
small interfering RNA (siRNA) to reduce endogenous IDE
expression. Human fibroblasts (MRC-5 cells) that are sus-
ceptible to productive VZV infection were transfected with
two independent pools of IDE-specific siRNAs (siRNA-
IDE1, siRNA-IDE2) or two independent control siRNA
pools (siRNA-1, siRNA-2). At 2.5 days after transfection,
half of the cells were harvested for immunoblotting to de-
termine the level of IDE, and the remainder of the cells was
infected with cell-free ROka-lacZ. IDE-specific siRNA
knocked down the IDE level by about 95% compared
with control siRNAs, as calculated by densitometry
(Figure 4A). To determine the effect of IDE knockdown
on VZV infection, the cells infected with cell-free ROka-
lacZ were stained with X-gal 4 days later. VZV infectivity
in the cells transfected with IDE-specific siRNA was re-
duced by about 70% compared with the cells transfected
with control siRNA (Figure 4B). Interestingly, most of the
X-gal positive foci in the cells transfectedwith IDE-specific
siRNA consisted of only single isolated blue cells
(Figure 4C, panels 3 and 4); in contrast, larger foci involv-
ing multiple cells, due to cell-to-cell spread of virus, were
Figure 3. Anti-IDE Antibodies and Soluble IDE Extracted from Liver Reduce VZV Infectivity and Virus Cell-to-Cell Spread
(A) Monoclonal anti-IDE antibody (50 ug/ml) or anti-gH antibody, but not control anti-CD3 antibody, inhibits the number of foci that stain with X-gal in
cells infected with ROka-lacZ. The figure shows the average of two independent experiments; P = 0.002 for anti-IDE antibody compared with medium
control.
(B) Polyclonal anti-IDE serum reduces the number of VZV-lacZ foci compared with normal rabbit serum or buffer controls. The figure shows the av-
erage of two independent experiments; p = 0.002 for anti-IDE 1/100 versus buffer; p < 0.001 for anti-IDE 1/100 versus preimmune serum.
(C) Plaque sizes are reduced in cells infected with cell-free VZV-lacZ treated with polyclonal anti-IDE serum (bottom panels) compared with cells
treated with normal rabbit serum (top panel). Magnification of 403.
(D) Purified soluble IDE protein extracted from liver (37.5 mg/ml) or anti-gH antibody, but not control soluble protein from uninfected cells, inhibits in-
fectivity in cells infected with cell-free ROka-lacZ. Virus was preincubated with soluble IDE at 37C for 30min before infection. Percentage of blue foci
is set at 100% for cells infected in the presence of media. P = 0.0004 by ANOVA.
(E) Plaque sizes in cells infected with cell-free VZV-lacZ treated with soluble IDE extracted from liver (3), but not medium (1) or control protein (2), are
reduced. Magnification of 1003.
(F) rIDE, but not BSA control or denatured rIDE (by pH 11.5), enhances VZV infectivity. Cell-free VZV-GFP virus was preincubatedwith rIDE at 20 mg/ml
at 37C for 30min before infection. Three days postinfection, GFP-positive foci were counted. P < 0.04 for rIDE versus buffer, denatured rIDE, or BSA.
The experiment was repeated with similar results. Error bars show standard deviations.present in the cells transfected with control siRNA
(Figure 4C, panels 1 and 2). Knockdown of IDE with
siRNA also inhibited infectivity of cell-associated wild-
type VZV (Figure 4D). Transfection with IDE-specific
siRNA did not reduce cell viability compared with control
siRNA.
Bacitracin, which Inhibits IDE, Blocks gE-IDE
Complex Formation, VZV Infection, and Cell-to-Cell
Spread
Since bacitracin inhibits IDE (Bennett et al., 2003), we ex-
amined the effect of the antibiotic on the interaction of gE
with IDE, VZV infectivity, and cell-to-cell spread. Bacitra-
cin was incubated with cell lysates in the presence of
gEt and immune complexes were immunoprecipitated
with anti-gE antibody and probed with antibody to IDE.
Bacitracin inhibited gEt-IDE complex formation in adose-dependent manner (Figure 5A). Bacitracin also in-
hibited the interaction of IDE with gE-Fc fusion protein
(G.L. and J.C., unpublished data). Bacitracin inhibited
plaque formation of cell-free VZV ROka-lacZ in a dose-
dependent manner with 90% reduction in infectivity at
5 mg/ml of antibiotic (Figure 5B).
Plaque size in the presence of 1 mg/ml of bacitracin,
added either at the time of infection or 8 hr after infection
to allow virus entry, was reduced, indicating that the drug
also reduced cell-to-cell spread of VZV. This effect was
observed in cells infected with either wild-type cell-
associated virus (Figure 5C) or with vaccine-derived cell-
free virus (Figure 5D). In contrast, bacitracin did not inhibit
either infectivity or cell-to-cell spread of HSV-1, but the
same dose of antibiotic inhibited cell-to-cell spread and
infectivity of VZV (Figure 5E). Bacitracin did not cause ap-
parent cytotoxicity and did not inhibit adenovirusCell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc. 309
Figure 4. Knockdown of Expression of IDE Blocks VZV Infectivity and Prevents VZV Cell-to-Cell Spread
(A) MRC-5 cells transfected with two independent specific IDE siRNA pools show reduced levels of IDE protein compared with cells transfected with
two independent nonspecific control siRNA pools.
(B) MRC-5 cells transfected with IDE siRNA and infected with cell-free ROka-lacZ show reduced numbers of foci that stain with X-gal at 4 days post-
infection, compared with cells transfected with control siRNA.
(C) MRC-5 cells transfected with IDE-specific siRNA and infected with cell-free ROka-lacZ (panels 3 and 4) show reduced size of infectious foci at 4
days after infection, compared with cells transfected with control siRNA (panels 1 and 2). Magnification of 1003.
(D) MRC-5 cells were transfected with siRNAs, and, after 2.5 days, the cells were infected with cell-associated wild-type (low-passage, Molly strain)
VZV for 1.5 hr and then washed twice to remove the inoculum. The cells were fixed 24 hr after infection, stained with mouse anti-gE antibody, followed
by FITC-conjugated anti-mouse antibody, and the number of immunofluorescent foci were counted. The figure represents the results of two inde-
pendent experiments.
Error bars show standard deviations, and t test was used to determine p values.infectivity at the doses used (data not shown). Thus, the
effect of bacitracin was specific for VZV and was not
seen with HSV-1, another human a-herpesvirus.
To ensure that the effects of bacitracin on VZV entry and
cell-to-cell spread were not due to an effect on virus rep-
lication, we performed electronmicroscopy on VZVROka-
infected cells in the presence or absence of bacitracin.
Bacitracin (1.0 mg/ml) was added to melanoma cells at 8
hr postinfection to allow viral entry. The cells were then in-
cubated for an additional 20 hr. Bacitracin did not reduce
nucleocapsid formation, virionmaturation, transport to the
cell surface, or the number of cell-surface virions when
compared with untreated controls (Figure S2). These310 Cell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc.data indicate that bacitracin did not inhibit VZV replication
or trafficking to the cell surface.
Expression of Exogenous Human IDE Increases VZV
Infectivity and Entry
To further investigate the function of IDE in VZV infection,
we performed a series of gain-of-function experiments.
Chinese hamster ovary (CHO) cells, which do not support
productive VZV infection, were transiently transfected
with either a plasmid expressing HA-tagged human IDE
or empty vector and infected with cell-free VZV-GFP virus.
This virus encodes GFP under a CMV promoter so that
productive infection is not required for expression of
Figure 5. Bacitracin, an IDE Inhibitor, Blocks IDE-gE Complex Formation, Inhibits VZV Infectivity, and Reduces Viral Cell-to-Cell
Spread
(A) Bacitracin reduces binding of soluble gE to IDE in a pull-down assay.
(B) Bacitracin reduces the number of X-gal positive foci in melanoma cells infected with cell-free ROka-lacZ 4 days postinfection.
(C) Bacitracin inhibits cell-to-cell spread of cell-associated wild-type VZV. Melanoma cells were infected with cell-associated low passage (Molly
strain) VZV in the presence or absence of bacitracin (1.0 mg/ml) for 24 hr. Cells were fixed and plaques stained with anti-gE antibody. Cell-to-cell
spread was determined by measuring plaque size of virus-infected cells (Collins and Johnson, 2003). The surface area of photographed plaques
in bacitracin-treated (N = 35) and -untreated (N = 51) cells was analyzed by Image J software. P values were calculated using a t test.
(D) Bacitracin reduces the size of plaques for melanoma cells infected with cell-free ROka-lacZ (lower panels, two representative fields), compared to
cells infected in the absence of the antibiotic (upper panels, 2 fields). Magnification of 1003.
(E) Bacitracin reduces the number and size of foci in melanoma cells infected with cell-free ROka-lacZ but not HSV-1-LacZ.
Error bars show standard deviations.GFP. Two days later, cells transfected with human IDE
showed a 3-fold increase in infectivity (Figure 6A). A mod-
est amount of virus was able to enter the cells (vector con-
trol) in the absence of human IDE, indicating that the cells
are not completely defective for entry. Similar results were
obtained with mouse melanoma cells (B78H1) infected
with VZV (data not shown). Since CHO and mouse mela-
noma cells do not support productive infection, the ability
of human IDE to increase the number of GFP-positive cells
after incubation with VZV suggests that the IDE is impor-
tant for a very early step in virus infection.
Tomeasure entry of VZV into cells, CHO cells that stably
express human IDE (B3 cells), or their parental control cell
line, were transfected with a reporter plasmid that en-
codes GFP under a T7 promoter. The CHO cells were
then incubated for 18 hr with melanoma cells infectedwith VZV-encoding T7 polymerase (ROka-T7). Expression
of the T7 promoter-driven GFP is turned on in cells in-
fectedwith ROka-T7. The level of GFP expression was de-
tected by anti-GFP antibody in immunoblot, and the
bands were quantified by densitometry. Cells stably ex-
pressing IDE showed a 3-fold increase in GFP expression,
indicative of enhanced entry when compared with control
cells (Figure 6B). A 3-fold increase in GFP expression was
also seen when porcine cells (SK-6 A7), which do not sup-
port productive VZV infection, cotransfected with the GFP
reporter plasmid, and plasmid expressing human IDE or
empty vector were used in place of CHO andCHOB3 cells
in the assay described above (unpublished data).
To determine whether exogenous expression of human
IDE in CHO cells enhances stable binding of VZV to the
cells, we transfected CHO cells with a plasmid expressingCell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc. 311
Figure 6. Expression of Exogenous Human IDE Increases VZV Entry and Infectivity and Rescues Impaired VZV Cell-to-Cell Spread
that Results from Knockdown of IDE
(A) Transfection of CHO cells with a plasmid encoding HA-tagged human IDE followed by infection with cell-free ROka-GFP increases the number of
GFP-positive foci, compared with cells transfected with control plasmid.
(B) Cells stably expressing human IDE show increased GFP by densitometry after transfection with a reporter plasmid that encodes GFP under a T7
promoter and incubation with cell-associated VZV encoding the T7 polymerase (ROka-T7), when compared with a control cell line that does not ex-
press human IDE. The result was repeated in three additional experiments using two different cell lines (CHO and SK6-A7), and the range of enhance-
ment of VZV entry by IDE was 2.2- to 12.5-fold.
(C) Transfection of CHO cells with HA-IDE results in increased binding of [35S]methionine labeled cell-free VZV compared with cells transfected with
control plasmid. Counts per minute (CPM) were obtained by subtracting those from lysates of uninfected cells from virus-infected cells. The binding
assay was performed in the presence of heparin to eliminate the contribution of attachment through cell-surface heparan sulfate. Error bars show
standard deviations, and t test was used to determine p values.
(D) Cotransfection of MRC-5 cells with control siRNA and plasmid expressing HA-IDE followed by infection with cell-free ROka-lacZ show increased
size of infectious foci (panel 2), compared with cells transfected with control siRNA and control plasmid (panel 1). Cells transfected with IDE-specific
siRNA and control plasmid and infected with ROka-lacZ show smaller-sized infectious foci (panel 3) than cells transfected with control siRNA and
control plasmid (panel 1). Cells transfected with IDE-specific siRNA and plasmid that expresses HA-IDE that is resistant to the siRNA, followed by
infection with ROka-lacZ, show increased size of infectious foci (panel 4), compared to cells transfected with IDE-specific siRNA and control plasmid
(panel 3).
Error bars show standard deviations.HA-tagged human IDE or control plasmid, and 2 days
later, the cells were incubated with radiolabeled cell-free
VZV in the presence of heparin at 4C for 1.5 hr to assay
for stable binding. Expression of human IDE increased
heparin-resistant binding of VZV to CHO cells by 1.6-
fold (Figure 6C). While the ability of exogenous human
IDE to increase VZV infectivity and binding was reproduc-
ible, the overall effect was somewhat modest. Endoge-
nous IDE in CHOcellsmay have interferedwith expression312 Cell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc.of exogenous human IDE and obscured the effect or ex-
pression of the human protein.
Expression of Exogenous Human IDE Corrects
the Defect in Cell-to-Cell Spread in IDE
Knockdown Cells
Since IDE knockout cells could not be obtained for
gain-of-function experiments, we cotransfected human
fibroblasts (MRC-5 cells) with IDE-specific siRNA to
Figure 7. The Level of Human IDE in Cells
Correlates with Infectivity by VZV
(A) Transfection of CHO cells with plasmid ex-
pressing HA-IDE or human IDE that is resistant
to siRNA (HA-IDE 2-2-B) followed by infection
with ROka-GFP increases the number of
GFP-positive foci in CHO cells.
(B) Autoradiogram of total IDE levels in trans-
fected cells. Transfection of CHO cells with
plasmids expressing IDE results in increased
levels of total (human plus CHO cells) IDE in
CHO cells. Beta-actin, detected with an anti-
body, was used as a loading control (data not
shown).
Error bars show standard deviations, and t test
was used to determine p values.knockdown endogenous human IDE and with a modified
plasmid expressing human IDE that should be resistant
to the IDE-specific siRNA. Plasmid HA-IDE2-2-Bwas con-
structed that encodes an HA epitope-tagged human IDE
with an altered nucleotide sequence that does not change
thepredicted aminoacid sequenceof IDEbut should resist
downregulation by siRNA IDE-02. Cotransfection of fibro-
blasts with siRNA IDE-02 and control plasmid, followed by
infectionwith cell-free ROka-lacZ, resulted in reduced size
of foci at 4 days after infection, indicative of impaired cell-
to-cell spread, compared with cells cotransfected with
control siRNA and control plasmid (Figure 6D, lines 1 and
3). The impairment in cell-to-cell spread was rescued by
transfection of cells with plasmid expressing siRNA-resis-
tant IDE (HA-IDE2-2-B) (Figure 6D, lines 3 and 4).
We cotransfected CHO cells with specific siRNA to
knockdown endogenous CHO IDE and infected the cells
with cell-free ROka-GFP 2 days later. Aliquots of the cells
were immunoblotted with anti-IDE Ab to verify the level of
IDE protein. Cotransfection of CHO cells with IDE-specific
siRNA and a control plasmid resulted in reduced levels of
endogenous IDE compared with cotransfection of the
cells with control siRNA and control plasmid (Figure 7,
lanes 4 versus 1). VZV infectivity in the cells was low. In
contrast, cotransfection of CHO cells with control siRNA
and either plasmid expressing unmodified (HA-IDE) ormodified (HA-IDE2-2-B) IDE resulted in increased levels
of IDE and a corresponding increase in VZV infectivity
(lanes 2 and 3). Cotransfection of cells with IDE-specific
siRNAandunmodifiedplasmid (HA-IDE) resulted in amod-
est increase in IDE levels and virus infectivity compared
with control siRNA and control plasmid (lanes 1 and 5).
In contrast, cotransfection of cells with IDE-specific siRNA
and siRNA resistant plasmid (HA-IDE2-2-B) resulted in
amore substantial increase in IDE levels and virus infectiv-
ity (lane 6). Thus, the level of VZV infectivity generally
correlated with the level of IDE expression.
DISCUSSION
Herewe show that VZV uses IDE as a receptor for infection
with cell-free virus and cell-to-cell spread of virus. While
four receptors were identified for HSV, each of these mol-
ecules interacts with HSV gD, and VZV lacks a gD homo-
log. While VZV gE coprecipitated with IDE, HSV gE inter-
acted with IDE much more weakly than its VZV homolog.
In addition, while bacitracin blocked IDE and inhibited
VZV infection and cell-to-cell spread, the antibiotic did
not reduce HSV infection or cell-to-cell spread. Although
HSV is closely related to VZV and has many homologous
genes, our data suggest that HSV does not use IDE as a
receptor. These studies allow us to begin to understandCell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc. 313
the mechanism of VZV entry and cell-to-cell spread. They
also identify gE as a receptor binding protein and confirm
a long-standing belief that gE may play an essential
role in VZV infectivity, either by cell-free or by cell-
associated virus.
IDE is a member of the zinc metalloproteinase family
that was initially implicated in insulin degradation
(Duckworth, 1988). It is highly conserved among different
species and has the ability to interact with a variety of
functionally unrelated ligands that share little homology
in their primary amino acid sequences. In addition to insu-
lin, glucagon, insulin-like growth factor II (IGF-II), atrial na-
triuretic peptide, transforming growth factor-a, and b-am-
yloid protein are substrates for IDE (Duckworth and
Kitabchi, 1974; Farris et al., 2003; Hamel et al., 1997; Mis-
bin and Almira, 1989; Muller et al., 1991). Several other
proteins, including epidermal growth factor and IGF-I,
bind to IDE but are not hydrolyzed by the enzyme (Duck-
worth et al., 1998). It has been hypothesized that these
IDE ligands possess common conformational motifs for
binding to IDE (Kurochkin, 1998).
Several other human viruses also use enzymes as re-
ceptors, notably human coronavirus 229E, which uses
aminopeptidase N (CD13), and human SARS-associated
coronavirus, which uses angiotensin-converting enzyme
2. Aminopeptidase N and angiotensin-converting enzyme
2 are, like IDE,members of the zincmetalloprotease family
(Delmas et al., 1992; Li et al., 2003). Interestingly, VZV as
well as the two coronaviruses use enzymes as receptors,
independent of the activity of the enzyme. Although IDE is
predominately a cytosolic protein, it is also present on the
plasma membrane (Goldfine et al., 1984; Kuo et al., 1993;
Yaso et al., 1987). It localizes to apical or basolateral re-
gions in different tissues (Kuo et al., 1993). A novel isoform
of IDE is associated with the surface of differentiated, but
not undifferentiated, neurons (Vekrellis et al., 2000). This
suggests that IDE may have a role in VZV infection of neu-
rons. IDE is also found in endosomes (Duckworth et al.,
1998; Hamel et al., 1991). HSV has recently been shown
to enter certain cells by endocytosis in a pH-dependent
pathway (Nicola et al., 2003). If VZV is endocytosed in
certain cells like HSV, then IDE might allow VZV in endo-
somes to penetrate into the cytosol. The tissue distribution
of IDE is ubiquitous (Kuo et al., 1993), which correlates
well with the broad tissue tropism of VZV, especially
in vivo.
Our results provide evidence to confirm the important
role of gE in VZV-mediated cell-to-cell spread. A naturally
occurring VZV mutant with a point mutation in gE shows
accelerated cell-to-cell spread in cell culture and in human
cells in SCID-hu mice (Santos et al., 2000). HSV gE, which
is homologous to the VZV glycoprotein, is necessary for di-
recting egress of virus to the basolateral surface of polar-
izedcells (Collins andJohnson, 2003;Dingwell et al., 1994).
Compared to other human herpes viruses, VZV is
unique in that it is transmitted from host to host as airborne
virus, yet it disseminates within the hosts by cell-to-cell
spread, similar to the pathway used for spread of virus in314 Cell 127, 305–316, October 20, 2006 ª2006 Elsevier Inc.cell culture (Arvin, 2001). Chen et al. (2004) demonstrated
that MPRci is important for cell-free, but not cell-associ-
ated, VZV infection. In contrast, IDE functions as a recep-
tor for both cell-free and cell-associated virus. IDE and
MPRci share some common features. Both molecules in-
teract with some of the same ligands, including IGF-I,
IGF-II, and epidermal growth factor (Kuo et al., 1993). At
the subcellular level, IDE and MPRci both localize abun-
dantly in endosomes, a compartment important for VZV
trafficking and maturation (Hambleton et al., 2004). There-
fore, IDE andMPRci might interact with each other to facil-
itate virus infection. Chen et al. (2004) showed that virus
maturation was altered in MPRci -deficient cells, and
cell-free virions were released into the medium in cell cul-
ture. In contrast, we did not detect a difference in virus
maturation by electron microscopy after treatment with
an IDE inhibitor (Figure S2), and inhibition of IDE did not re-
sult in release of detectable cell-free infectious virus into
the cell-culture media (Q.L. and J.C., unpublished data).
Many viruses have evolved to use multiple receptors to
augment their infectivity. Two observations from our ex-
periments suggest the possibility that VZV may use
more than one receptor. First, blocking IDE resulted in
only 25%–75% reduction of VZV infection and cell-to-
cell spread. A similar limit on the maximum degree of in-
hibitory efficiency has been seen with other viruses that
use more than one receptor (Akula et al., 2002; Cocchi
et al., 1998; Shukla et al., 1999). Second, expression of ex-
ogenous human IDE in nonhuman cells rendered them
more susceptible to VZV infectivity than to virus binding.
It is likely that VZV uses another molecule, in addition to
IDE, to bind to cells. Investigations are currently underway
to identify other cellular molecules that are important for
VZV binding and infection.
In summary, we have identified IDE as a cellular recep-
tor for infection by cell-free and cell-associated VZV. VZV
glycoprotein gE, which is essential for virus infection, in-
teracts with IDE through its extracellular domain. Inhibitors
of IDE may have a role in the treatment or prevention of
VZV infection.
EXPERIMENTAL PROCEDURES
Cells and Viruses
Human fibroblasts (MRC-5), melanoma (MeWo, fromC. Grose, Univer-
sity of Iowa), HeLa, CV-1/EBNA (ATCC, Manassas, VA), T (II-23) cells
(from C. Ware, La Jolla Institute for Allergy and Immunology) that are
susceptible to VZV infection (Zerboni et al., 2000), B78H1 mouse
melanoma cells (from N. Fraser, University of Pennsylvania), CHO
cells, B3 CHO cells that express human IDE (Vekrellis et al., 2000)
(from R. W. Farris, Harvard University), 3T3, and SK-6 A7 cells (from
O. Fuller, University of Michigan), were used.
VZV strains ROka (recombinant derived Oka), Molly (a low passage
isolate), ROka-lacZ (expressing b-galactosidase) (Cohen et al., 1998),
ROka-GFP expressing GFP, or ROka-T7 expressing T7 polymerase
(Supplemental Data) were grown inmelanoma cells. HSV-1 expressing
b-galactosidase was a gift from P. Schaffer (Cai and Schaffer, 1991).
Cell-free virus was prepared by scraping cells from flasks in SPGC
buffer (10% fetal bovine serum, 0.1% sodium glutamate, 5% sucrose
in PBS), freeze thawing the cells once, sonicating the lysate,
centrifuging the lysate at 1,2403 g for 10 min at 4C, and transferring
the supernatant to a new tube for use as cell-free virus.
Antibodies and Reagents
Rabbit polyclonal anti-IDE-1 (provided by R.W. Farris), murine mono-
clonal anti-IDE 9B12, and rabbit polyclonal anti-IDE antibody, PRB-
282C (both from Covance, Berkeley, CA), were used to detect IDE.
Soluble IDE protein purified from liver was provided by Dr. R. Bennett
(University of Nebraska). Anti-VZV monoclonal antibodies to gE
(Chemicon, Temecula, CA), gI, gB (Biodesign, Saco, Maine), and gH
(from C. Grose) were used. Bacitracin (Sigma-Aldrich, St. Louis, MO)
was dissolved in water. Control Fc fusion proteins including P7.5-Fc
(encoding the vaccinia 7.5 protein), were provided by M. Spriggs.
Plasmids
The extracellular domain of gE (amino acids 1–537) was amplified by
PCR with SalI and BamHI linkers and inserted into plasmid pDC409
(Giri et al., 1994) to generate plasmid pDC409-gEt. The extracellular
domain of gE, along with an in-frame C-terminal human Ig-Fc tag,
was cloned into pDC409 to generate plasmid pDC409-gE-Fc. The ex-
tracellular domain of gI (amino acids 1–271) was amplified by PCR and
cloned into pDC409 to create plasmid pDC409-gIt. PEF6/V5-His-HA-
IDE (Vekrellis et al., 2000) encoding HA-tagged human IDE was pro-
vided by R.W. Farris. A 3.3 kb (BamHI-NotI) fragment encoding HA-
IDE from plasmid pEF6/V5-His-HA-IDE was inserted into baculovirus
vector pVL1393 (BD Biosciences Pharmingen, San Diego, CA). Plas-
mid expressing full-length HSV-2 gE (pcDNA3-gE) was provided by
J. Weir (FDA, Bethesda, MD).
Recombinant gE and Biotinylation of Proteins
CV-1/EBNA cells were transfected with plasmids expressing gEt or
gE-Fc using Lipofectamine (Invitrogen, Carlsbad, CA) with low Ig
FBS (HyClone, Logan, UT). Five days after transfection, tissue culture
supernatants were collected. For biotinylation of cell-surface proteins,
cell monolayers were incubated with 0.5 mg/ml of EZ-Link Sulfo-NHS-
Biotin (Pierce) in PBS (pH8.0) for 30 min at 25C followed by three
washes with cold PBS.
RNA Interference and Ligand Binding Assay
IDE-specific siRNASmartPools (siRNA-IDE1 and siRNA-IDE2) and two
nonspecific control pools (Duplex-13 and C8-scrumple) were synthe-
sized by Dharmacon (Lafayette, CO). Each pool contains four individ-
ual siRNA duplex sequences. IDE-specific individual siRNA duplex
IDE-02 contains sequence ACACUGAGGUUGCAUAUUUUU (sense
sequence). Cells were transfected with 100 nM of individual siRNA
or siRNA pools using nucleofection (Amaxa, Gaithersburg, MD).
Histidine (His)-tagged soluble gE and gI (Kimura et al., 1997), gB
(R. Williams and S. Straus, personal communication), and HA-tagged
IDE were each cloned into baculovirus, and proteins were purified
fromSf9-infected cells. HA-IDE protein was coated onto 96-well plates
at 4C for 18 hr. After washing, equal amounts of gEt-His, gIt-His, or
gBt-His protein (normalized by ELISA using anti-His antibody) were
added and incubated at 4C for 3 hr. The plates were washed, anti-
His-HRP secondary antibody was added, TMB one-step substrate
(Dakocytomation, Carpinteria, CA) was added, and binding capacity
was detected at OD450 nm by an ELISA reader.
Supplemental Data
Supplemental Data include four figures and experimental procedures
and can be found with this article online at http://www.cell.com/cgi/
content/full/127/2/305/DC1/.
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